+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

A case study from the chemistry core of the Pittsburgh Molecular Library Screening Center: the Polo-like kinase polo-box domain (Plk1-PBD)



A case study from the chemistry core of the Pittsburgh Molecular Library Screening Center: the Polo-like kinase polo-box domain (Plk1-PBD)



Current Topics in Medicinal Chemistry 9(13): 1194-1205



The Polo-like kinase (Plk) family comprises four cell cycle serine/threonine kinases, Plk1-4. Among these, Plk1 has been most thoroughly characterized; it contains a conserved kinase domain and a C-terminal docking site for S/T-phosphorylated proteins (polo-box domain, PBD). Polo-like kinases are deregulated in oncogenesis and therefore constitute a therapeutic target for cancer. A high throughput screening campaign was carried out by the Pittsburgh Molecular Library Screening Center (PMLSC), using a fluorescence polarization assay with recombinant Plk1-PBD to monitor the inhibition of binding of an optimal phosphopeptide substrate motif with recombinant Plk1-PBD. Screening of 97,090 small molecule library samples provided by the NIH Small Molecule Repository distributed by DPI Galapagos led to 11 confirmed hits. The Pittsburgh MLSCN Chemistry Core selected one of the structurally most tractable hits, SID 861574, for chemical hit-to-probe development. A broad chemistry program was initiated that developed new strategies for 6-amino- and 6-hydroxy uracil synthesis as well as acylanilides, and generated a total of 70 analogs. Out of 46 analogues tested, none, nor the resynthesized hit, showed affinity to Plk1-PBD in the follow up assays. In contrast, re-assays of the original screening materials displayed activities similar to the original HTS assay. We ultimately concluded that an impurity in the commercial material led to the positive screening artifact. This case study highlights our development of a synthesis of 6-position functionalized uracil analogs, but also illustrates the importance of careful quality and compound stability monitoring of screening collections.

(PDF emailed within 1 workday: $29.90)

Accession: 051097225

Download citation: RISBibTeXText

PMID: 19807663


Related references

Identification of high affinity polo-like kinase 1 (Plk1) polo-box domain binding peptides using oxime-based diversification. Acs Chemical Biology 7(5): 805-810, 2012

Non-proteinogenic amino acids in the pThr-2 position of a pentamer peptide that confer high binding affinity for the polo box domain (PBD) of polo-like kinase 1 (Plk1). Bioorganic and Medicinal Chemistry Letters 22(24): 7306-7308, 2013

A selective inhibitor of the Polo-box domain of Polo-like kinase 1 identified by virtual screening. Journal of Advanced Research 16: 145-156, 2019

The Polo-box domain: a molecular integrator of mitotic kinase cascades and Polo-like kinase function. Cell Cycle 3(2): 128-131, 2004

Computational analysis of phosphopeptide binding to the polo-box domain of the mitotic kinase PLK1 using molecular dynamics simulation. Plos Computational Biology 6(8), 2010

Development of cyclic peptomer inhibitors targeting the polo-box domain of polo-like kinase 1. Bioorganic and Medicinal Chemistry 21(9): 2623-2634, 2013

Selective Degradation of Polo-like Kinase 1 by a Hydrophobically Tagged Inhibitor of the Polo-Box Domain. Angewandte Chemie 2018, 2018

Identification of inhibitors of the polo-box domain of polo-like kinase 1 from natural and semisynthetic compounds. Investigational New Drugs 2019, 2019

A fluorescence polarization assay for the discovery of inhibitors of the polo-box domain of polo-like kinase 1. Methods in Molecular Biology 795: 69-81, 2012

Identification of nitroimidazole-oxime derivatives targeting the polo-box domain of polo-like kinase 1. Bioorganic and Medicinal Chemistry 25(24): 6581-6588, 2017

Identification of green tea catechins as potent inhibitors of the polo-box domain of polo-like kinase 1. Chemmedchem 10(1): 158-163, 2015

In vivo tumor imaging using polo-box domain of polo-like kinase 1 targeted peptide. Biomaterials 33(29): 6915-6925, 2012

Identification of a novel Polo-like kinase 1 inhibitor that specifically blocks the functions of Polo-Box domain. Oncotarget 8(1): 1234-1246, 2016

Identification of novel and selective non-peptide inhibitors targeting the polo-box domain of polo-like kinase 1. Bioorganic Chemistry 81: 278-288, 2018

Peptoid–Peptide Hybrid Ligands Targeting the Polo Box Domain of Polo-Like Kinase. 2012